Pharmacogenomics & Precision Medicine

February 25, 2026

Patients with atrial fibrillation face higher bleeding risks when treated with 2 common medications

While diltiazem remains an effective option for heart rate control in selected patients, bleeding risk posed by anticoagulants should be considered.

Dan Roden, MD, chats with colleagues during a break in the symposium. (photo by Erin O. Smith)
October 1, 2025

Symposium honors personalized medicine leader Dan Roden

Roden is internationally known for his contributions to understanding arrhythmias and to the field of pharmacogenomics.

September 5, 2025

Dan Roden awarded Vanderbilt’s Earl Sutherland Prize for Achievement in Research

He received the award for his pioneering work focusing on leveraging genetic information to enhance health care outcomes.

July 1, 2025

New lab for transplant, other specialized testing launches at Vanderbilt Medical Laboratories

The new Histocompatibility and Immunogenetics Laboratory launched its first phase of testing June 26 and ultimately will fully support clinical testing for the Vanderbilt Transplant Center, the nation’s third busiest transplant center by volume.

Members of the Kang lab include (front row from left) Melissa Deleeuw, Jing-Qiong (Katty) Kang, MD, PhD, Wangzhen Shen, MD, and Karishma Randhave, and (back row from left) Ekta Anand, Debbie Song, and Kirill Zavalin, PhD. (photo by Susan Urmy)
December 10, 2024

Therapy for genetic epilepsy in children showing promise

Preliminary results of a clinical trial of 4-phenylbutyrate (PBA) “show a significant reduction in seizure activity among participants.”

October 18, 2024

All of Us tour stops at VUMC Oct. 22-25

The All of Us Research Program brings the future of health to VUMC and Nashville.